A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of
ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive
disease.